Previous studies have shown that increased PD‐L1 expression enhances the efficacy of anti‐PD‐L1 antibodies.[49, 50] Combining siPFKFB4/PRLPTX@RBCM‐cRGD with anti‐PD‐L1 antibodies resulted in synergistic therapeutic effects, significantly suppressing tumor growth, thereby providing a strong theoretical basis for combining chemotherapy with immunotherapy in clinical applications. This evidence concerns the gene CD274 and neoplasm.